Colin Rees
YOU?
Author Swipe
View article: Overview of the COLOFIT study
Overview of the COLOFIT study Open
Objective There are 44 000 new cases of colorectal cancer (CRC) and 16 000 deaths in the UK annually. Most CRCs are diagnosed following symptom development; however, symptoms are poorly predictive of CRC. Around 700,000 patients are referr…
View article: Multimethod study of Endoscopic Retrograde Cholangio Pancreatography (ERCP) service delivery: stakeholder perspectives on opportunities for quality improvement
Multimethod study of Endoscopic Retrograde Cholangio Pancreatography (ERCP) service delivery: stakeholder perspectives on opportunities for quality improvement Open
Background and aims Endoscopic Retrograde Cholangio Pancreatography (ERCP) is a technically challenging and relatively risky procedure. The British Society of Gastroenterology ERCP Endoscopy Quality Improvement Programme was established to…
View article: External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics
External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics Open
Background A faecal immunochemical test (FIT) result ≥ 10 µg/g is recommended in the UK to triage patients with symptoms of colorectal cancer (CRC) in primary care for urgent cancer investigation. The COLOFIT model combining FIT results wi…
View article: Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies Open
Background The human gut microbiome is of academic and clinical interest. Associations between certain organisms and colorectal neoplasia have been reported, but findings have limited reproducibility in different populations. Methods We pe…
View article: Understanding mechanisms of colorectal cancer chemoprevention using seAFOod polyp prevention trial outcomes and its Biobank: STOP-ADENOMA synopsis
Understanding mechanisms of colorectal cancer chemoprevention using seAFOod polyp prevention trial outcomes and its Biobank: STOP-ADENOMA synopsis Open
Background The 2 × 2 factorial seAFOod trial demonstrated that aspirin and omega-3 polyunsaturated fatty acid eicosapentaenoic acid reduce colorectal polyp number (a biomarker of colorectal cancer risk) during colonoscopy surveillance in t…
View article: Healthcare provision for cancer survivors with chronic bowel symptoms post pelvic radiotherapy. “… and then you're kind of cast adrift”: A qualitative study
Healthcare provision for cancer survivors with chronic bowel symptoms post pelvic radiotherapy. “… and then you're kind of cast adrift”: A qualitative study Open
Our findings suggest a need for raising awareness of late-effects of pelvic-radiotherapy among patients and health professionals encompassing recognition of symptoms and awareness of treatments and support and for accelerating access to sp…
View article: Patient experiences and expectations of faecal immunochemical testing for investigation of colorectal cancer symptoms: a cross-sectional qualitative interview study with patients and practitioners in the UK
Patient experiences and expectations of faecal immunochemical testing for investigation of colorectal cancer symptoms: a cross-sectional qualitative interview study with patients and practitioners in the UK Open
Objectives Faecal immunochemical testing (FIT) is now commonplace in the UK to prioritise symptomatic patients for urgent gastrointestinal investigation. The test requires a stool sample to be collected at home by the patient and returned …
View article: Clinician-reported Gloucester Comfort Scale scores underestimate patient discomfort and pain during colonoscopy: insights from comparison with a patient-reported experience measure
Clinician-reported Gloucester Comfort Scale scores underestimate patient discomfort and pain during colonoscopy: insights from comparison with a patient-reported experience measure Open
Patient experience is a fundamental element of colonoscopy. The Gloucester Comfort Scale (GCS) is used by clinicians to report patient comfort. However, insights regarding the extent to which clinician-reported GCS scores represent the pat…
View article: <scp>COLOFIT</scp> : Development and Internal‐External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients
<span>COLOFIT</span> : Development and Internal‐External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients Open
Background Colorectal cancer (CRC) is the third most common cancer in the United Kingdom and the second largest cause of cancer death. Aim To develop and validate a model using available information at the time of faecal immunochemical tes…
View article: Cost-effectiveness of FIT and a FIT-based model to optimise symptomatic diagnosis of colorectal cancer: health economic modelling for the COLOFIT project
Cost-effectiveness of FIT and a FIT-based model to optimise symptomatic diagnosis of colorectal cancer: health economic modelling for the COLOFIT project Open
Introduction Fecal immunochemical testing (FIT) at a threshold of 10 mg haemaglobin (Hb)/g is used in English primary care to prioritise urgent referral for colorectal cancer (CRC) investigation in symptomatic patients. The COLOFIT algorit…
View article: The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial Open
Analysis of the seAFOod trial according to the change in EPA concentration, instead of treatment allocation, revealed a protective effect of EPA treatment on colorectal polyp recurrence (ISRCTN05926847).
View article: Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment
Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment Open
Background Nonattendance at colonoscopy is associated with reduced colorectal cancer (CRC) survival. Purpose The aim of this research was to quantify barriers to colonoscopy and test the effectiveness of behavior change techniques (BCTs) t…
View article: ‘I Do It All Alone’: The Burdens and Benefits of Being Diagnosed With, and Treated for, Colorectal Cancer During the Covid‐19 Pandemic
‘I Do It All Alone’: The Burdens and Benefits of Being Diagnosed With, and Treated for, Colorectal Cancer During the Covid‐19 Pandemic Open
Introduction The Covid‐19 pandemic dramatically altered the way cancer care services were accessed and delivered, including for colorectal cancer (CRC). In the United Kingdom, patients were discouraged from presenting in primary care, many…
View article: Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Table 2 shows the results of Negative binomial regression analysis of total colorectal polyp number according to aspirin use stratified for each SNP
View article: Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Table 1 shows the list of SNPs that were analysed by the Fluidigm assay.
View article: Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Aspirin and eicosapentaenoic acid (EPA) reduce colorectal adenomatous polyp risk and affect synthesis of oxylipins including prostaglandin E2. We investigated whether 35 SNPs in oxylipin metabolism genes such as cyclooxygenase (PTGS) and l…
View article: Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
seAFOod trial participants and samples contributing to the gene × treatment interaction analysis. 666 of 707 seAFOod trial participants provided at least one buffy coat sample for DNA extraction. The number of samples lost during either DN…
View article: Table 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Table 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
SNP genotypes in ALOX genes and the TP53 gene that are associated with modification of the effect of aspirin on colorectal polyp number in the seAFOod polyp prevention trial.
View article: Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Aspirin and eicosapentaenoic acid (EPA) reduce colorectal adenomatous polyp risk and affect synthesis of oxylipins including prostaglandin E2. We investigated whether 35 SNPs in oxylipin metabolism genes such as cyclooxygenase (PTGS) and l…
View article: Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Figure 3 shows the distribution of individual total (combined adenomatous and serrated polyp) colorectal polyp counts according to seAFOod trial treatment allocation by factorial margins and TP53 rs104522 genotype.
View article: Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Figure 1 shows the distribution of individual total (combined adenomatous and serrated polyp) colorectal polyp counts according to seAFOod trial treatment allocation by factorial margins and PTGS SNP genotypes.
View article: Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Table 1 shows the list of SNPs that were analysed by the Fluidigm assay.
View article: Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Supplementary Figure 3 shows the distribution of individual total (combined adenomatous and serrated polyp) colorectal polyp counts according to seAFOod trial treatment allocation by factorial margins and TP53 rs104522 genotype.
View article: Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
SNP genotypes in PTGS genes that are associated with modification of the effect of aspirin on colorectal polyp number in the seAFOod polyp prevention trial.
View article: Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Open
Clinical characteristics of the study cohort of 542 seAFOod trial participants who had a SNP genotype profile and trial colonoscopy outcome data.